EJ
Publicaties op Oncologisch.com
Nivolumab plus relatlimab in gevorderd melanoma: RELATIVITY-047 4-year update.
Three-Year Totale overleving With Nivolumab Plus Relatlimab in Gevorderd Melanoma From RELATIVITY-047.
QoL met nivolumab plus relatlimab versus nivolumab bij melanoom: RELATIVITY-047 analyse
Relatlimab plus nivolumab versus nivolumab bij onbehandeld gevorderd melanoom: RELATIVITY-047 fase II/III